Future research aims to better understand the complex interactions within the Bcl-2 family and to develop more effective and selective inhibitors. Novel strategies include dual-targeting BH3 mimetics and combination therapies that integrate traditional chemotherapy with Bcl-2 inhibitors. Additionally, identifying biomarkers that predict response to Bcl-2 targeted therapies could personalize and optimize treatment for cancer patients.
